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Abstract  
Ischemic stroke continues to be a leading cause of mortality and morbidity in the world. 
Despite recent advances in the field of stroke medicine, thrombolysis with recombinant 
tissue plasminogen activator remains as the only pharmacological therapy for stroke 
patients. However, due to short therapeutic window (4.5 hours of stroke onset) and 
increased risk of hemorrhage beyond this point, each year globally less than 1% of stroke 
patients receive this therapy which necessitate the discovery of safe and efficacious 
therapeutics that can be used beyond the acute phase of stroke. Accumulating evidence 
indicates that endothelial progenitor cells (EPCs), equipped with an inherent capacity to 
migrate, proliferate and differentiate, may be one such therapeutics. However, the limited 
availability of EPCs in peripheral blood and early senescence of few isolated cells in culture 
conditions adversely affect their application as effective therapeutics. Given that much 
of the EPC-mediated reparative effects on neurovasculature is realized by a wide range 
of biologically active substances released by these cells, it is possible that EPC-secretome 
may serve as an important therapeutic after an ischemic stroke. In light of this assumption, 
this review paper firstly discusses the main constituents of EPC-secretome that may exert 
the beneficial effects of EPCs on neurovasculature, and then reviews the currently scant 
literature that focuses on its therapeutic capacity.
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Introduction 
According to the World Health Organization, each year 
about 15 million people suffer a first stroke in the world. 
Sadly, while one-third of these patients die, another one-
third live with long-term disabilities inflicted by this condition 
(Ma et al., 2015). Hence, stroke continues to be one of the 
major causes of mortality and morbidity worldwide (Hisham 
and Bayraktutan, 2013; Liao et al., 2017). Ischemic strokes, 
stemming from an interruption of blood flow to the brain, 
make up about 80–85% of all strokes. Despite being the main 
cause of human cerebral damage, systemic thrombolysis with 
recombinant tissue plasminogen activator or endovascular 
treatment remain the only therapeutic options for this disease 
(Allen and Bayraktutan, 2009; Reis et al., 2017). However, 
due to short therapeutic window and stringent eligibility 
criteria, each year less than 1% of stroke patients worldwide 
receive either therapy (Hacke et al., 2008; Bayraktutan, 2019). 
This necessitates the discovery of novel therapeutic agents 
that can be safely and effectively used beyond the acute (or 
hyperacute) phase of ischemic stroke. Although over the 
years many agents targeting various mechanisms associated 
with ischemic stroke, such as excitotoxicity or oxidative 
stress, have generated favorable results in experimental 
settings, subsequent clinical trials have failed to replicate 
these favorable outcomes. As depicted in Figure 1, complexity 
of human neurovascular unit (NVU), a dynamic structure 
formed by direct contact, signaling and interactions amongst 
microglia, astrocytes, neurons and endothelial cells, has been 
proposed to explain this apparent dichotomy (Serlin et al., 
2015). Blood-brain barrier (BBB) makes up a critical part of 
this unit and is composed of brain microvascular endothelial 
cells (BMECs), capillary basement membrane (BM), pericytes 
embedded in the BM and astrocyte end-feet enclosing the 
blood vessels (Ballabh et al., 2004; Zehendner et al., 2009). 
Although its structural and functional integrity are critical in 
maintaining cerebrovascular homeostasis, the BBB is also an 
important obstacle for the delivery of so-called efficacious 
therapeutics. The BMECs cover the entire luminal part of all 
brain capillaries and constitute the main cellular component 
of the BBB. They differ from the endothelial cells of other 
organs in that they are joined together with tight junction 
proteins, lack fenestrae, have low number of intracellular 
mitochondria and possess specific transport systems that 
actively carry the nutrients from blood to the brain (Petty 
and Lo, 2002; Weiss et al., 2009). Tight junctions limit passive 
molecular diffusion through the BBB by forcing molecular 
traffic away from paracellular routes to transcellular routes 
(Wolburg and Lippoldt, 2002; Nag, 2003; Abbott et al., 2006). 
The BM surrounds the BMECs, accommodates pericytes, 
makes connections with astrocyte end-feet and appears to 
play a role in tight junction formation (Carvey et al., 2009). 
The pericytes enclose the blood vessel wall, make direct 
contact with the BMECs, facilitate angiogenesis and play a role 
in preserving microvascular stability (Zhao et al., 2015). The 
astrocyte end-feet enclose the outer side of the blood vessels, 
help maintain the integrity and function of the BBB and block 
the differentiation of pericytes from resting to a contractile 
stage (Yao et al., 2014). 
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Sudden decreases in cerebral blood flow during an ischemic 
stroke may perturb NVU structural integrity and impair 
overall cerebral function through involvement of a series of 
mechanisms including depleted generation of adenosine 
triphosphate, excitotoxicity, oxidative stress and inflammation 
(Lipton and Rosenberg, 1994; del Zoppo and Hallenbeck, 
2000; Allan and Rothwell, 2001; Doyle et al., 2008; Williams-
Karnesky and Stenzel-Poore, 2009; Deb et al., 2010; Martin 
and Wang, 2010; Woodruff et al., 2011; Xing et al., 2012; 
Fann et al., 2013; Brennan-Minnella et al., 2015; Prakash and 
Carmichael, 2015). As illustrated in Figure 2, excitotoxicity 
harms NVU through increases in sodium and calcium influx 
triggered by accumulation of extracellular excitatory amino 
acids, glutamate and aspartate (Lipton and Rosenberg, 
1994; Williams-Karnesky and Stenzel-Poore, 2009; Deb et 
al., 2010; Martin and Wang, 2010; Woodruff et al., 2011; 
Xing et al., 2012; Fann et al., 2013; Brennan-Minnella et al., 
2015). Oxidative stress and post-ischemic inflammation, 
characterized by excessive availabilities of reactive oxygen 
species (ROS) and inflammatory cytokines such as interleukin 
(IL)-1β, IL-18, IL-6 and tumor necrosis factor-α harm NVU by 
disrupting structural integrity of the tight junctions (del Zoppo 
and Hallenbeck, 2000; Allan and Rothwell, 2001; Doyle et al., 
2008; Fann et al., 2013; Prakash and Carmichael, 2015). 
Search Strategy 
For the present review, we searched the literature using 
keywords such as endothelial progenitor cells, outgrowth 
endothelial cells, blood outgrowth endothelial cells, circulating 
endothelial colony forming cells, EPCs, OECs, secretome, 
growth factors, chemokines, cytokines, adhesion molecules, 
proteases, shed receptors, release, secrete, secretion, 
ischemia, infarction, vascular injury, endothelial injuries, 
reperfusion injury, stroke, cerebral damage, cerebrovascular 
disease, cerebral artery disease, and cerebrovascular 
accident on PubMed, Embase, Web of Sciences, Cochrane 
Central Library and Google Scholar. In addition, we also used 
modifications of the above main keywords to thoroughly 
search the literature. The major inclusion criteria preferred the 
literature comprising endothelial progenitor cells, secretome, 
ischemic stroke, and growth factors. 
Endothelial Progenitor Cells 
The inability to replicate favorable results obtained in 
translational studies has spurred stroke research community 
to explore new therapeutics that can simultaneously and 
effectively influence major mechanisms implicated in the 
pathogenesis of ischemic stroke (Deb et al., 2010). In this 
context, cell-based approaches, especially those with 
endothelial progenitor cells (EPCs) have attracted much of 
the attention (Condon et al., 2004; Di et al., 2009). EPCs are 
equipped with an inherent capacity to proliferate, migrate 
and differentiate into few other cells including mature 
endothelial cells. Considering that endothelial cells constitute 
Review
the main cellular component of the BBB and help maintain 
vascular homeostasis through regulation of vascular tone, 
coagulation and inflammation, replacement of dead or dying 
endothelial cells by EPCs is thought to be of considerable 
therapeutic value for patients with ischemic stroke. However, 
the sparsity of EPCs in circulation necessitates their isolation, 
characterization and expansion before re-administration as 
autologous or allogeneic therapeutics.
EPCs were first isolated as a subtype of peripheral blood 
mononuclear cells (Asahara et al., 1997) and later classified 
into two subtypes, early EPCs which appear after 3–5 days 
in culture, have spindle-shaped morphology and the late 
EPCs (also known as outgrowth endothelial cells (OECs)) 
which appear within 2–4 weeks after seeding and display 
cobblestone morphology (Hur et al., 2004; Bayraktutan, 2019). 
The OECs express angiogenic characteristics and are fully 
committed to the endothelial lineage (Medina et al., 2010). A 
recent study assessing the reparative impact of early EPCs and 
OECs on endothelial layer of a well-established in vitro model 
of human BBB, composed of endothelial cells, astrocytes and 
pericytes, has shown that only OECs can restore integrity and 
function of BBB by physical incorporation into the site of injury 
(Abdulkadir et al., 2020). In this regard, in vivo studies proving 
the safety and efficacy of autologous EPC transplantation 
also exist (Zhu et al., 2008). In addition to repairing damaged 
cerebral barrier, EPCs also contribute to neovascularization by 
modulating the content of their secretome and enhancing cell 
migration, proliferation and angiogenesis as a consequence 
(Kalka et al., 2000; Urbich et al., 2003, 2005a; Yamaguchi et al., 
2003; Di et al., 2009; Gallina et al., 2015; Felice et al., 2018). 
As application of EPC-secretome may eliminate the risks 
associated with transplantation of live cells including emboli, 
infection and immune incompatibility, EPC-free approach may 
actually be a better therapeutic option. Table 1 summarizes 
the main benefits affiliated with treatments with EPC-
secretome in that the possibility of an off-the-shelf application 
opens a new avenue in the field of regenerative medicine 
and deserves to be investigated as a potential therapeutic 
for ischemic stroke (Ballmoos et al., 2010; Seminatore et al., 
2010; Lodi et al., 2011; Rosell et al., 2013; Vizoso et al., 2017).
Analysis of Endothelial Progenitor Cell 
Secretome
The term “secretome” is defined as a set of molecules, 
including of growth factors, chemokines, cytokines, free 
nucleic acids, lipids and extracellular vesicles, secreted or 
shed from living cells. The secretome may be stratified into 
Figure 1 ｜ Schematic representation of neurovascular unit. Figure 2 ｜ Schematic representation of the effect of ischemic stroke on 
neurovascular unit.
A sudden disruption in cerebral blood flow and ensuing decreases in oxygen 
and energy supply triggers oxidative stress and compromises the integrities of 
tight junctions and blood-brain barrier (BBB). Overproduction of inflammatory 
cytokines and excitotoxicity further damage neuronal loss and BBB 
damage thereby leading to formation of cerebral edemas. ATP: Adenosine 
triphosphate; ECs: endothelial cells; IL: interleukin; ROS: reactive oxygen 
species; TNFα: tumor necrosis factor α.
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microparticles, apoptotic bodies and exosomes (Tjalsma 
et al., 2000; Makridakis et al., 2010, 2013; Pavlou and 
Diamandis, 2010; Skalnikova et al., 2011; Beer et al., 2017). 
Of these, the exosomes are of particular interest due their 
ability to control intracellular communications by mediating 
the transfer of lipids, proteins or RNAs to the target cells. 
Exosomes are small vesicles that range between 40–150 nm 
in size (De Jong et al., 2014; Li et al., 2016). EPC-exosomes are 
surrounded by a bilayer of lipids and have a cup or biconcave 
morphology which protect them from enzymatic degradation 
and enable them to serve as transportation cargoes in the 
body (Yellon and Davidson et al., 2014; Vicencio et al., 2015; 
Kong et al., 2018). By increasing the expression of vascular 
endothelial growth factor (VEGF) and endothelial nitric oxide 
synthase, EPC-exosome appears to promote the survival, 
proliferation and tubulogenic activity of endothelial cells 
(Zhang et al., 2019) while inhibiting vascular leakage in lungs 
and kidneys (Zhou et al., 2018). Furthermore, EPC-exosome 
has been shown to inhibit neointima formation and enhance 
angiogenesis in both in vitro and in vivo settings like a rodent 
model of carotid artery injury (Sahoo et al., 2011; Kong et al., 
2018). Recent evidence demonstrates that similar to EPC-
derived exosome, EPC-derived mitochondria also help protect 
NVU from ischemic damage by incorporating into endothelial 
cells and increasing intracellular adenosine triphosphate 
levels and tight junctional tightness (Hayakawa et al., 2018; 
Borlongan, 2019). 
Like mature endothelial cells, EPCs are also able to secret 
a wide range of substances with different mechanism of 
action (Table 2). Shotgun proteomics and difference gel 
electrophoresis studies have identified 82 proteins in the 
conditioned media of human early EPCs (EPC-CM) which 
include various members of cathepsin family, proangiogenic 
substances like chemokine ligand 18, hemoglobin scavenger 
receptor CD163 and thymidine phosphorylase and few anti-
oxidant enzymes such as mitochondrial superoxide dismutase 
and hemoxygenase-1 (Urbich et al., 2011). The 71 out of 
these 82 proteins in EPC-secretome appeared to be different 
from those of CD14+ monocytes and human umbilical veins 
endothelial cells (Urbich et al., 2011). By culturing cells in 
growth factor-free medium over a period of 72 hours, Rehman 
et al. (2003) have found that late EPCs release granulocyte 
colony-stimulating factor (G-CSF), VEGF, hepatocyte growth 
factor and granulocyte-macrophage colony-stimulating factor 
as angiogenic growth factors. Additional studies have shown 
that human EPC-CM also contains chemokines, thrombo-
inflammatory mediators and adhesion molecules. Interestingly, 
while thrombo-inflammatory mediators such as tissue factors 
are secreted mainly by early EPCs, those regulate migration 
and infiltration of monocytes or macrophages, e.g., monocyte 
chemoattractant protein-1 are mainly released by late EPCs 
(Zhang et al., 2009). These add further weight to the previous 
studies indicating that early EPCs and OECs represent distinct 
EPC populations. Indeed, while cultured early EPCs express 
many genes linked to immunity and inflammation such as toll-
like receptors, human leukocyte antigens and CD14 (Medina 
et al., 2010), OECs express the markers of senescence and 
Table 1 ｜ Comparative impact of treatments with EPCs and EPC-secretome
 EPCs therapy EPC-secretome therapy 
Risk of infection + + + + 
Risks of immune incompatibility  + + + +
Emboli formation + + + 
Need for toxic agents for 
cryopreservation
+ + +
Preparation time + + +
Cost + + +
EPCs: Endothelial progenitor cells.
produce greater levels of cytokines. Inflammatory elements 
such as IL-8, IL-6, IL-1β and IL-1α have been identified as 
the major facilitators of OEC senescence (Medina et al., 
2013). In light of the evidence, treatments with early EPC 
or OEC secretome should be conducted with care to avoid 
exacerbation of pre-existing inflammatory response in the 
ischemic microenvironment. 
Possible Mechanisms of Action of Endothelial 
Progenitor Cell Secretome in Ischemic Stroke    
Anti-inflammatory activity 
Inflammation, characterized by the exaggerated release 
of pro-inflammatory cytokines, e.g., IL-1β, IL-6 and tumor 
necrosis factor-α, represents one of the main mechanisms 
that develop following a cerebral ischemic injury. Stroke 
patients with localized (cerebral) or systemic inflammation 
exhibit clinically poorer outcome (Allan and Rothwell, 2001; 
Fann et al., 2013; Abdullah and Bayraktutan, 2016). Through 
concurrent regulation of various anti-inflammatory cytokines 
and inflammatory genes such as Brahma, IκB and Foxf1, 
EPCs attenuate the toxic and apoptotic tendencies of the 
inflammatory milieu. In support of this notion, co-culture of 
human EPCs with human endothelial cells has been shown 
to significantly block the elevations of aforementioned pro-
inflammatory genes during experimental ischemic stroke. 
Likewise, intracerebral administration of late EPCs into animal 
model of ischemic stroke (after 4 hours) has also been shown 
to improve neurological recovery up to 30 days post cell-
therapy by significantly downregulating the gene expression 
of Brahma, IKB and Foxf1 in the cortex and striatum (Tajiri 
et al., 2012; dela Peña et al., 2015; Acosta et al., 2019). In 
accordance with these findings, administration of EPC-CM 
into a rat model of spinal cord injury has been found to induce 
functional recovery where attenuation of apoptosis, M1 
macrophage activation and IL-6 release along with stimulation 
of angiogenesis appeared to aid functional recovery (Wang 
et al., 2018). Similar to these observations, intratracheal 
administration of EPC-exosome to a mice model of acute lung 
injury has also significantly reduced chemokine, cytokine and 
protein concentrations in the bronchoalveolar lavage fluid, 
further supporting the anti-inflammatory and tissue-protective 
effects of EPC-secretome (Zhou et al., 2019). In another study, 
reinfusion of a specific paracrine factor, namely thymosin B4 
released by embryonic EPCs has diminished infarct size in 
pigs subjected to myocardial ischemia and enhanced post-
hypoxic cardiomyocyte survival by moderating post-ischemic 
inflammatory responses (Hinkel et al., 2008).   
Tissue repair and angiogenic regulation
Discovery of an abundance of highly mitogenic cytokines, 
notably IL-8 and angiogenin in EPC-CM strongly implies 
that EPC-secretome can readily stimulate the chemotactic, 
proliferative and tubulogenic capacity of endothelial 
cells (He et al., 2005). Post-stroke administration of EPC-
secretome rich in angiogenic factors may help facilitate 
vascular repair and suppress neointima formation by inducing 
proliferation of the resident endothelial cells at the site of 
vascular damage (Paneni et al., 2016). It is of note here that 
the process of angiogenesis, involving the activation and 
migration of endothelial cells, is also regulated by cytokines 
and chemokines (Gnecchi et al., 2008). Transplantation of 
OEC-secretome rich in cytokines and chemokines has been 
coupled to marked increases in the angiogenic capacity 
of brain BMECs in a mouse model of chronic cerebral 
hypoperfusion and in in vitro settings (Di Santo et al., 2014). 
Furthermore, greater availability of different growth factors 
such as VEGF and IGF-1 has also been implicated in increased 
angio-neurogenesis in the ischemic area of stroke rats treated 
with late EPCs (Urbich et al., 2005b; Moubarik et al., 2011; 
Schneller et al., 2019). 
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Antioxidant capacity 
Oxidative stress, emerging from an imbalance between 
pro- and anti-oxidants, is another major mechanism that 
can induce or worsen cerebrovascular damage following 
an ischemic cerebral injury (Allen and Bayraktutan, 2009). 
Compared to mature endothelial cells, EPCs possess 
significantly higher total antioxidant capacity. Indeed, greater 
expression of antioxidant enzyme glutathione peroxidase, Mn-
containing superoxide dismutase and catalase enables EPCs 
to tolerate a certain degree of oxidative stress (Dernbach et 
al., 2004) and potentiates their vasoreparative and angiogenic 
capacities in both ischemic and inflammatory settings. For 
instance, treatments with late EPC-secretome has been 
shown to mitigate the deleterious effects of oxidative stress 
on BBB during and after an ischemic stroke (Dernbach et al., 
2004) and reduced the extent of oxidative injury in human 
umbilical veins endothelial cells by augmenting the expression 
of antioxidant enzymes, Mn- and CuZn-containing superoxide 
dismutase (Yang et al., 2011). 
Migration and tissue invasion   
EPCs also regulate cellular chemotaxis by modulating the 
release of prominent pro-angiogenic factors like VEGF, SDF-
1, IGF-1 and hepatocyte growth factor. Increases in VEGF and 
SDF-1 also facilitate adhesion and recruitment of EPCs to the 
site of ischemic and non-ischemic damage (Anderson et al., 
2015). Similarly, EPC-secretome has been shown to increase 
mobilization, proliferation and migration of various progenitor 
and resident vascular cells like cardiac progenitor cells and 
endothelial cells, respectively. Increased migration of mature 
endothelial cells to the site of limb ischemia in rats treated with 
human EPC-CM corroborates this notion (Urbich et al., 2005a).   
Apart from growth factors and cytokines, EPCs also synthesize 
and release many lysosomal peptidases including cathepsin L, 
cathepsin D, cathepsin H and cathepsin O. Bearing in mind that 
inhibition of these enzymes, in particular that of cathepsin L, 
has abated the invasion, incorporation and function of EPCs in 
a model of hindlimb ischemia (Urbich et al., 2005b), specific 
targeting of these peptidases may prove to be instrumental 
in controlling the recruitment of EPCs to the site of injury. It 
is possible that EPC-secretome supplemented with cathepsin 
L may substantially induce homing and incorporation of 
circulating EPCs to the site of ischemic cerebral injury. Figure 3 
summarizes potential mechanism of action of EPC secretome 
on NVU during and after ischemic stroke. 
Key Mechanisms Associated with Modification 
of Endothelial Progenitor Cell Secretome 
Hypoxia is regarded as the main element that can enhance 
the migratory and angiogenic capacities of transplanted cells 
(Wei et al., 2012; Morancho et al., 2013). As exposure of EPCs 
to hypoxia promotes secretion of a series of growth factors, 
notably VEGF, VEGF-D, PDGF-BB, epidermal growth factor, 
basic fibroblast growth factor as well as angiogenin, leptin 
and thrombopoietin, it is likely that CM obtained from EPCs 
subjected to hypoxia can augment the regenerative potential 
of native and transplanted progenitor cells (Di Santo et al., 
2014). Indeed, such treatment has recently been shown 
to induce mobilization of EPCs from bone marrow and led 
to increases in hindlimb blood flow and capillary density 
while inhibiting apoptosis of mature endothelial cells (Di 
Santo et al., 2009). Furthermore, application of hypoxic EPC-
CM entrapped in polymer-based nanoparticles, carriers for 
controlled release of EPC secretome, has also been shown to 
increase blood perfusion and capillary formation in ischemic 
limb model (Felice et al., 2018). EPCs grown under hypoxic 
conditions have been shown to secrete 647 proteins. Of these, 
83 appear to be differentially regulated compared to the cells 
grown under normoxic conditions. While the expression of 
17 of these 83 proteins, mostly angiogenic factors including 
protein S100 family, apolipoprotein E, protease inhibitors are 
upregulated by hypoxia, the expression of 12 proteins, notably 
dermcidin, trypsin-1, cystatin-C and calcium-binding protein 
39 appear to be downregulated (Felice et al., 2018). 
Inflammation or inflammatory reactions can also influence 
Table 2 ｜ Important paracrine factors of endothelial progenitor cell-secretome
Factors                                                  Function References
Angiogenin                                                                                        Angiogenesis, migration, proliferation  Di Santo et al. (2009); Maki et al. (2018) 
Hepatocyte growth factor Angiogenesis, motility, morphogenesis Rehman et al. (2003); Di Santo et al. (2009)
Interleukin-8 Chemoattraction, proliferation, angiogenesis   Urbich et al. (2005); Di Santo et al. (2009); Pula et al. (2009) 
Platelet derived growth factor B Angiogenesis, proliferation, recruitment  Di Santo et al. (2009)
Stromal derived factor-1 Angiogenesis, antipoptosis, migration Di Santo et al. (2009); Paneni et al. (2016); Maki et al. (2018) 
Vascular endothelial growth factor Migration, proliferation, angiogenesis  Rehman et al. (2003) 
Vascular endothelial growth factor A Migration, mitogenesis, angiogenesis Urbich et al. (2005); Di Santo et al. (2009); 
Pre-B cell-enhancing factor Angiogenesis, antipoptosis  Pula et al. (2009) 
Matrix metalloproteinase-9 Angiogenesis, migration, proliferation  Rehman et al. (2003); Pula et al. (2009)
Macrophage migration inhibitory factor Angiogenesis, migration, recruitment  Pula et al. (2009)
Cathepsins Invasion, angiogenesis  Urbich et al. (2005); Pula et al. (2009); Urbich et al. (2011)
Protease inhibitors Angiogenesis, migration, invasion  Pula et al. (2009)
S100 proteins Angiogenesis, proliferation, invasion  Pula et al. (2009)
Thymidine phosphorylase Angiogenesis, antipoptosis, migration  Pula et al. (2009)
2-deoxy-D-ribose-1-phosphate Migration, angiogenesis Pula et al. (2009)
Mitochondrial superoxide dismutase Antioxidants, antipoptosis Dernbach et al. (2004); Urbich et al. (2011)
Homoxygenase-1 Antioxidant, antipoptosis Dernbach et al. (2004); Urbich et al. (2011)
Alternative macrophage markers C-C motif 
chemokine 18
Healing, migration Urbich et al. (2011)
Haemoglobin scavenger receptor CD163 Adhesion, anti-inflammation Urbich et al. (2011)
Cytokine-like 1 Angiogenesis, migration  Schneller et al. (2019)
Platelet-derived growth factor AA/AB/BB Angiogenesis, proliferation, recruitment  Urbich et al. (2005); Maki et al. (2018)
Vascular endothelial growth factor B Angiogenesis, migration Urbich et al. (2005); Maki et al. (2018)
Granulocyte-macrophage colony-stimulating 
factor
Angiogenesis, proliferation, antipoptosis    Rehman et al. (2003)
Granulocyte colony-stimulating factor Proliferation, differentiation, angiogenesis  Rehman et al. (2003); De Jong et al. (2014)
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the number and functionality of EPCs. Inflammatory factors 
such as GM-CSF and SDF-1 enhance mobilization of EPCs from 
bone marrow (Takahashi et al., 1999; Tousoulis et al., 2008). 
For example, the increases seen in number of functional late 
OECs mirrored increases in plasma levels of VEGF, SDF-1 and 
IL-8 in burned patients within the first 24 hours of hospital 
admission (Rignault-Clerc et al., 2013). Another study focusing 
on the mobilization of EPCs in two different groups of patients 
with acute vascular injury emerging from burns or coronary 
artery bypass grafting has also revealed substantial increases 
in circulatory EPC numbers and coupled these to significant 
increases in plasma VEGF and cytokine levels (Gill et al., 2001). 
These findings suggest that enrichment of EPC-secretome 
by exposure to inflammatory stimuli in in vitro settings may 
potentiate its therapeutic impact in in vivo settings through 
recruitment of resident EPCs from bone marrow to the site of 
ischemic injury.  
As indicated above, oxidative stress radically contributes 
to the pathogenesis and progression of ischemic stroke. 
Genetic manipulation of factors associated with the release 
or neutralization of ROS is therefore likely to influence the 
content of EPC-secretome and its therapeutic efficacy. 
Mammalian adaptor p66Shc and JunD, a member of the 
activated protein-1 family of transcription factors which 
modulate mitochondrial ROS production and vascular cell 
senescence have attracted some attention in this context. 
Indeed, compared to OECs obtained from young donors, OECs 
of old subjects express significantly higher levels of p66Shc 
(pro-oxidant) and the lower level of the activated protein-1. 
However, genetic manipulation of OECs isolated from elderly 
donors through silencing of p66Shc or overexpression of JunD 
has been shown to attenuate age-driven ROS generation by 
reinstating a balance between pro-oxidant and anti-oxidant 
enzymes and enhance SDF-1 expression in conditioned media 
(Paneni et al., 2016). 
Therapeutic Potential of Endothelial Progenitor 
Cell Secretome
Considering that proteins secreted into conditioned media in 
in vitro conditions mimicking an ischemic injury are likely to be 
representative of those found in circulation following a cerebral 
ischemic episode, their analysis and accurate identification are 
of profound diagnostic, prognostic and therapeutic importance 
(Stastna and Van Eyk, 2012). In light of the reports illustrating 
post-ischemic increases in circulating numbers of EPCs, it is 
safe to propose that similar increases in the synthesis and 
release of constituents that make up EPC-secretome may also 
Figure 3 ｜ Possible mechanism of action of EPC secretome on restoration 
of neurovascular unit during or after an ischemic stroke. 
EPC-secretome containing many biologically active substances such as growth 
factors, cathepsins, cytokines and chemokines may evoke endogenous 
regeneration and neovascularization by activating resident endothelial cells, 
inhibiting oxidative stress and concomitantly inducing angiogenesis and 
neurogenesis. EC: Endothelial cell; EPC: endothelial progenitor cell.
go up which in turn substantiate their diagnostic value (Sobrino 
et al., 2007). While regenerative potential of EPC-secretome 
is somewhat well-documented in experimental settings, to 
our knowledge there is currently no clinical study that has 
assessed the putative therapeutic role of EPC-secretome after 
an ischemic stroke. In fact, phase I and phase II clinical trials 
of intravenous transplantation of allogenic mesenchymal stem 
cells for patients with chronic ischemic stroke (> 6 months 
of onset) have been shown to be safe and associated with 
significant behavioral gain over a 12-month follow up (Levy et 
al., 2019). As the microenvironment affecting the NVU after 
an ischemic stroke is under persistent change (Liao et al., 
2017), while designing prospective clinical trials, the timing 
of treatments with EPC-secretome is an important factor 
to take into consideration. Transplantation of EPCs or EPC-
secretome rich in VEGF, PDGF-BB and fibroblast growth factor 
into a mouse model of ischemic stroke, within 30–32 hours 
of ischemic stroke, has been shown to enhance capillary 
density in the peri-infarct areas and improved functional 
strength of forelimbs. The improvements in functional aspects 
remained noticeable at 2 weeks following ischemic injury 
and were largely attributed to the appearance of additional 
blood vessels in the peri-infarct areas (Rosell et al., 2013). 
Intravenous injection of EPCs into a rodent model of transient 
ischemic stroke 24 hours after the occlusion of middle cerebral 
artery also led to a significant functional recovery within two 
weeks. Given that the direct incorporation of EPCs into rat 
neovasculature could not be visualized in this study, functional 
improvements observed might actually be due to the paracrine 
effects of EPC-secretome (Moubarik et al., 2011). A relevant 
study testing the angiogenic capacity of early (within 1 hour of 
stroke) and late (48 hours after stroke) administration of VEGF, 
a key component of EPC-secretome, to a rodent model of 
ischemic stroke has generated some interesting findings in that 
while the former approach compromised the integrity of the 
BBB and promoted hemorrhagic transformation in the focal 
ischemic lesions, the latter approach enhanced angiogenesis in 
the ischemic penumbra and significantly improved neurological 
recovery. Taken together these findings imply that future 
therapeutic strategies considering exogenous administration 
of EPC-secretome should pay a very close attention to the 
treatment start time and adjust the concentration of EPC-
secretome according to the phase of ischemic stroke; 
hyperacute, acute, subacute versus chronic (Zhang et al., 
2000). 
Similar to the beneficial effects observed after ischemic stroke, 
EPC-derived factors have been shown to protect cultured 
cortical neuronal progenitor cells from a metabolic injury 
induced by glucose and serum deprivation (Santo et al., 2020). 
Again, transplantation of EPCs to a mice model of traumatic 
brain injury led to elevations in neovasculogenesis and 
neurological recovery. Here, stimulation of axonal outgrowth 
of neurons along with increased proliferation, survival and 
recruitment of resident EPCs to the site of ischemic brain 
injury by key constituents of EPC secretome, namely VEGF, 
SDF1 and proangiogenic cytokines, was thought to play a 
critical role (Zhang et al., 2013). EPC secretome-mediated 
suppression of inflammation alongside the regulation of 
angiogenesis, functional recovery and axonal regeneration 
has also been implicated in neuroprotection in a rat model 
of spinal cord injury (Wang et al., 2018). Furthermore, 
intravenous administration of EPC-secretome to mice at 24 
hours and 7 days of permanent bilateral occlusion of carotid 
arteries has also been associated with promotion of vascular 
density and protection of cognitive function in a mouse 
model of white matter injury following prolonged cerebral 
hypoperfusion (Maki et al., 2018). In light of these studies, it 
is reasonable to suggest that administration of EPC-secretome 
to patients with ischemic stroke beyond the hyperacute phase 
of the disease may be beneficial. Table 3 summarizes the 
major benefits of EPC-secretome in pre-clinical settings. 
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Conclusion 
It is evident that EPCs secrete a vast range of substances 
with differing function. Evidence gathered from an increasing 
number of in vitro and in vivo studies suggest that these 
factors may help repair the damaged neurovasculature after 
an ischemic stroke by inducing mobilization, proliferation, 
migration and homing of resident or circulatory progenitor 
cells to the damaged vasculature. Available evidence also 
indicates that timing of post-stroke administration of EPC-
secretome is of crucial importance to improve neurological 
outcome and to prevent hemorrhagic transformation. 
However, well-thought future studies scrutinizing the 
therapeutic potential and efficacy of EPC-secretome in 
laboratory, translational and clinical settings are required 
before a cell-free treatment regimen can become a 
therapeutic possibility for patients with ischemic stroke.
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